Lilly reports positive data for breast cancer drug
Eli Lilly is gearing up to file data for its experimental breast cancer drug abemaciclib after it was found to slow disease progression in a late-stage trial.
Read More
Tag: MONARCH
Lilly’s experimental breast cancer drug slips in trial
Lilly’s experimental breast cancer therapy abemaciclib has failed to hit interim efficacy targets in a late-stage combination trial, but the study will continue as planned on the recommendation of an independent data monitoring committee.
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
